NCT00607386 - Safety and Clinical Outcomes in Hunter Syndrome Patients 5 Years of Age and Younger Receiving Idursulfase Therapy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2007

Primary Completion Date

July 8, 2011

Study Completion Date

July 8, 2011

Conditions

Hunter SyndromeMucopolysaccharidosis IIMPS II

Interventions

BIOLOGICAL

Idursulfase

Solution for intravenous infusion, 0.5 mg/kg weekly

Trial Locations (3)

National Taiwan University Hospital, Dept. of Pediatrics and Medical Genetics, Taipei

Hospital de Clinicas de Porto Alegre, Servico de Genetica Medica, Porto Alegre

Instytut Pomnik Centrum Zdrowia Dziecka, Klinika Chorob Metaboliczynch, Endokrynologii i Diabetologii, Warsaw